Keratoderma is a group of diseases, whose common symptom is increased keratinization due to increase in the amount of the keratinocytes along with decrease in their normal desquamation. Excessive keratinization of the palmar skin suppresses tactile sensitivity, which causes discomfort, and cracks lead to disability. Objective — the research was aimed at studying the possibilities of using Uroderm in the treatment of patients with acquired localized keratoderma. Material and methods. We formed two groups of patients, which were similar in terms of main characteristics: group 1 included 37 patients (10 males and 27 females) diagnosed with palmoplantar psoriasis, group 2 included 39 females diagnosed with climacteric keratoderma. Both groups applied Uroderm ointment BID for 30 days. Results. Significant decrease in the area of lesions compared to the baseline was observed in both groups (up to 44% in group 1 and 19% in group 2). Significant decrease in the dermatological index values as assessed on symptom scale and Visual Analogue Scale was found: from 9.64±3.71 and 3.39±1.08 points to 2.13±1.04 and 1.19±0.83 points, respectively, in group 1; from 10.31±3.45 and 3.67±0.97 points to 1.01±0.62 and 0.57±0.57 points, respectively, in group 2. Application of Uroderm ointment resulted in relatively fast clinical cure in group 1 — 16 (43,2%) of 37 patients and significant improvement in group 2 — 31 (79,5%) patients of 39. Conclusion. Uroderm ointment has a significant positive effect on the severity of the basic objective clinical manifestations of localized keratoderma. The drug in characterized by high safety and tolerability: there were no complications in both groups of patients; none of the study patients had episodes of allergy or individual intolerance.